Beam Therapeutics Inc. (BEAM) financials: revenue, earnings and cash flow
Fiscal 2019–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Beam Therapeutics’s revenue went from $18000 in fiscal 2019 to $140M in fiscal 2025, growth of about 345.0% a year.
Net income in fiscal 2025 was -$80M, a net margin of -57.2%; the best year in this period was 2019 with -$78M.
Over the twelve months to September 30, 2026, revenue was $147M and net income -$108M.
Free cash flow was -$360M in fiscal 2025 and positive in 0 of the 7 years shown.
The diluted share count rose 1426% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $147M | $140M | $64M | $378M | $61M | $52M | $24000 | $18000 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$393M | -$384M | -$416M | -$176M | -$338M | -$392M | -$133M | -$75M |
| Net income | -$108M | -$80M | -$377M | -$133M | -$289M | -$371M | -$195M | -$78M |
| EPS (diluted) | $-0.87 | $-0.81 | $-4.58 | $-1.72 | $-4.13 | $-5.77 | $-4.19 | $-14.05 |
| R&D | $409M | $410M | $368M | $437M | $312M | $387M | $103M | $55M |
| Revenue growth | — | +120.0% | −83.2% | +520.0% | +17.5% | +215900.0% | +33.3% | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$389M | -$345M | -$347M | -$149M | $23M | -$66M | -$96M | -$72M |
| Capital spending | -$10M | -$15M | -$9M | -$34M | -$49M | -$47M | -$16M | -$13M |
| Free cash flow | -$398M | -$360M | -$356M | -$183M | -$26M | -$113M | -$112M | -$85M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — |
| Stock-based pay | $77M | $94M | $121M | $99M | $84M | $44M | $15M | $7M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash | — | $1.2B | $851M | $436M | $233M | $560M | $300M | $92M |
| Debt | — | $154M | $161M | $173M | $179M | $142M | $100M | $26M |
| Equity | — | $1.2B | $734M | $981M | $733M | $827M | $246M | -$201M |
| Total assets | — | $1.5B | $1.1B | $1.5B | $1.3B | $1.5B | $452M | $156M |
| Shares (diluted) | 105M | 99M | 82M | 77M | 70M | 64M | 47M | 6M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -267.7% | -274.6% | -654.2% | -46.7% | -555.6% | -757.0% | -553200.0% | -417500.0% |
| Net margin | -73.9% | -57.2% | -593.1% | -35.1% | -474.5% | -714.9% | -810800.0% | -435100.0% |
| FCF margin | -271.6% | -257.6% | -560.8% | -48.4% | -43.4% | -218.1% | -467100.0% | -469600.0% |
| ROIC | — | -27.6% | -36.7% | -12.1% | -29.3% | -40.5% | -38.4% | — |
| ROE | — | -6.5% | -51.4% | -13.5% | -39.4% | -44.8% | -79.2% | 39.0% |
Frequently asked questions
What is Beam Therapeutics’s annual revenue?
$140M in fiscal 2025 and $147M over the twelve months to September 30, 2026.
How much profit does Beam Therapeutics make?
Net income was -$80M in fiscal 2025 (net margin -57.2%).
Is Beam Therapeutics’s revenue growing?
Yes: revenue rose 120.0% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.